Medications for Invasive Pulmonary Aspergillosis

10 results

  • Caspofungin acetate (caspofungin acetate)

    (Caspofungin Acetate)
    Fosun Pharma USA Inc.
    Usage: Caspofungin acetate is indicated for empirical treatment of presumed fungal infections in febrile, neutropenic patients, and for treating candidemia, various Candida infections, esophageal candidiasis, and invasive aspergillosis in patients intolerant to other therapies, with specific limitations for certain conditions.

  • Caspofungin acetate (caspofungin acetate)

    (CASPOFUNGIN ACETATE)
    Areva Pharmaceuticals
    Usage: Caspofungin acetate is indicated for empirical therapy of presumed fungal infections in febrile, neutropenic patients, treatment of candidemia and other Candida infections, esophageal candidiasis, and invasive aspergillosis in patients intolerant to other therapies. It is not approved for certain conditions like oropharyngeal candidiasis or initial invasive aspergillosis therapy.

  • Caspofungin acetate (caspofungin acetate)

    (Caspofungin Acetate)
    Gland Pharma Limited
    Usage: Caspofungin acetate is indicated for the empirical treatment of presumed fungal infections in febrile, neutropenic patients, treatment of candidemia, esophageal candidiasis, and invasive aspergillosis in patients intolerant to other therapies, in adults and pediatric patients aged 3 months and older. Limitations apply for specific infections.

  • Posaconazole (posaconazole)

    (posaconazole)
    Par Pharmaceutical Inc.
    Usage: Posaconazole delayed-release tablets are indicated for treating invasive aspergillosis in patients aged 13 and older. It also prophylaxes invasive Aspergillus and Candida infections in severely immunocompromised patients. The oral suspension is approved for treating oropharyngeal candidiasis, including cases resistant to itraconazole or fluconazole in patients 13 and older.

  • Posaconazole (posaconazole)

    (posaconazole)
    Mylan Institutional LLC
    Usage: Posaconazole injection is indicated for treating invasive aspergillosis in patients aged 13 and older and for prophylaxis against invasive Aspergillus and Candida infections in severely immunocompromised patients, including those with graft-versus-host disease or prolonged neutropenia from chemotherapy, starting at age 2.

  • Vfend (voriconazole)

    (Voriconazole)
    Roerig
    Usage: VFEND is indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in adults and pediatric patients (2 years and older) intolerant to or refractory to other therapies.

  • Voriconazole (voriconazole)

    (voriconazole)
    Sandoz Inc
    Usage: Voriconazole tablets are indicated for the treatment of invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in patients aged 2 years and older, particularly those intolerant or refractory to other therapies.

  • Voriconazole (voriconazole)

    (Voriconazole)
    Greenstone LLC
    Usage: Voriconazole is indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. in patients 2 years and older who are intolerant or refractory to other therapies.

  • Voriconazole (voriconazole)

    (voriconazole)
    Slate Run Pharmaceuticals
    Usage: Voriconazole for injection is indicated for adults and pediatric patients (2 years and older) to treat invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium species, especially when other therapies are ineffective or intolerable.

  • Voriconazole (voriconazole)

    (Voriconazole)
    Eugia US LLC
    Usage: Voriconazole for injection is indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in patients intolerant to or refractory to other therapies. Suitable for adults and pediatric patients aged 2 years and older.